UK-based Mundipharma International Corp. Ltd. has added to its biosimilar basket with the acquisition of Cinfa Biotech, and with it, immediate access to revenues from the recently-approved Pelmeg, a biosimilar to Amgen Inc.’s neutropenia therapy Neulasta (pegfilgrastim).
While the terms of the deal were undisclosed, Mundipharma estimates the global market for Pelmeg to be up to $4